MindWalk Holdings (HYFT) Q2 2026 earnings review
Leaner, Faster, Tech-Focused: The Post-Divestiture Pivot Works
MindWalk (formerly ImmunoPrecise Antibodies) has fundamentally altered its financial profile following the divestiture of its European wet lab operations. The remaining 'Bio-Native AI' business is smaller in absolute terms but significantly higher quality. Revenue from continuing operations surged 54% YoY to $4.1M, while gross margins expanded dramatically to 65% (up from 51%). The sale of the Dutch subsidiary provided a critical cash injection, boosting reserves to $16.5M. However, a material weakness in internal controls regarding accounting complexity remains a serious governance red flag.
🐂 Bull Case
Gross margin jumped to 65% from 51% a year ago. This expansion validates the strategic pivot away from capital-intensive services toward the higher-margin LensAI and BioStrand software-led model.
Despite a 54% increase in revenue, Total Operating Expenses remained flat YoY ($5.4M). The company is scaling revenue without adding incremental overhead, a key indicator of software scalability.
🐻 Bear Case
Management admitted disclosure controls are 'not effective' due to insufficient resources to handle complex technical accounting. For a public company dealing with M&A and complex IP, this is a significant governance risk.
While the divestiture boosted cash to $16.5M, the company still posted a Net Loss from continuing operations of $3.2M for the quarter. Without the one-time sale proceeds, the runway would be critical.
⚖️ Verdict: 🟢
Constructive. The financials finally reflect the 'AI company' narrative management has pitched for years. The explosive growth in continuing operations (+54%) combined with flat OpEx is the golden ratio for tech investors. Governance issues prevent a higher grade.
Key Themes
Project Revenue Acceleration
Accelerating. Project revenue—the core indicator of demand for MindWalk's discovery services and LensAI integration—grew 55% YoY to $4.06M. This segment now accounts for 98% of total revenue, confirming that the legacy 'product sales' model is effectively obsolete for the new entity.
Accounting & Control Failures
A specific material weakness was identified: the company lacks sufficient resources to address 'complex technical accounting issues.' While remediation plans (hiring consultants) are underway, this creates risk regarding the accuracy of financial reporting, particularly concerning the accounting of the recent divestiture and earnouts.
Divestiture of Europe B.V.
The sale of the Dutch subsidiary (IPA Europe B.V.) to AVS Bio closed in August 2025, netting ~$10.2M USD. This move was strategic subtraction: it removed lower-margin revenue to capitalize the balance sheet for the AI push. The accounts have been restated to show 'Continuing Operations,' revealing a much healthier core business than prior consolidated numbers suggested.
Internal Asset Progression (Dengue & GLP-1)
MindWalk is moving beyond services into asset creation. LensAI identified a conserved epitope for a universal dengue vaccine and supported the design of GLP-1 receptor agonists for longevity. These assets offer optionality: they can be out-licensed for high-margin revenue, validating the platform's utility to partners.
Dependence on Non-Dilutive Funding
With a quarterly Net Loss of $3.2M and $16.5M in cash, the company has roughly 4-5 quarters of runway at the current burn rate. Management states cash is sufficient for 'at least one year,' but to extend beyond 2026 without dilution, they must drastically reduce burn or close a major licensing deal.
Other KPIs
Accelerating. Up 94% YoY. The mix shift is working: higher-margin tech revenues are outpacing the fixed costs of the remaining wet lab operations.
Stable. Increased only 7.7% YoY. Controlling G&A while revenue grows 54% demonstrates discipline, though this line item remains high relative to total revenue (74% of revenue).
Improved significantly from $10.7M at fiscal year-end (April 2025), primarily driven by the asset sale. This buys the company time to execute the SaaS transition.
Guidance
Stable. Management asserts cash is sufficient for at least one year from issuance. This removes the immediate 'Going Concern' panic that plagued previous quarters, but the clock is ticking.
Contingent liability remains through April 2029. No amounts paid yet, implying the subsidiary has not yet hit profitability triggers, which aligns with the current investment phase.
Key Questions
Remediation Timeline
You identified a material weakness regarding technical accounting resources. What is the specific timeline for remediation, and will correcting this require restatements of prior periods?
LensAI SaaS Metrics
With Gross Margins expanding to 65%, can you break out the specific contribution of recurring SaaS/Subscription revenue versus one-time project fees within the Project Revenue line?
Burn Rate Post-Divestiture
Now that the Dutch operations are sold, what is the normalized quarterly cash burn rate for the remaining MindWalk entity? Is the Q2 Net Loss of $3.2M representative of the forward run rate?
Asset Monetization
Regarding the internal programs (Dengue, GLP-1): Are you actively seeking out-licensing partners for these assets in FY26, or is the strategy to develop them further internally?